American pharmacist, Union Army officer, businessman, philanthropist
Eli Lilly Is Cracking Down on an Experimental Weight-Loss Drug. Georgia Clinics Are Promoting It Anyway
trib.al/9vnLPq7
Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
scientificamerican.com/article/blockbuster-retatrutide-trial-signals-a-new-high-water-mark-for-weight-loss-drugs/
Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion
qz.com/eli-lilly-innocare-drug-discovery-deal-3-billion-092426
Eli Lilly's Mounjaro (tirzepatide) is now FDA-approved to reduce cardiovascular risk in adults with type 2 diabetes (T2D) ... Show more
State approves $98 million electricity project for Eli Lilly property: Dominion said the Goochland project is needed to provide electricity for the planned ...
richmond.com/news/local/business/article_085f8f43-2a1e-4959-b3f9-96f7216e901c.html
Mounjaro sales soar 502% as India's GLP-1 drug market expands rapidly: Mounjaro Sales in India: Mounjaro has overtaken other GLP-1 medicines to become India's ...
business-standard.com/health/mounjaro-sales-soar-502-as-india-s-glp-1-drug-market-expands-rapidly-126091000479_1.html
Novo Nordisk: Too many factors speak against a quick turnaround: Novo Nordisk is one of the biggest beneficiaries of the boom in slimming drugs ...
themarket.ch/unternehmen/novo-nordisk-zu-viele-faktoren-sprechen-gegen-einen-baldigen-turnaround-ld.17608
Big, Bold, Breaking Ground: Why Eli Lilly, Amazon And Mastercard Headline Our New Most Innovative Large Companies List
forbes.com/sites/hnewman/2026/08/25/big-bold-breaking-ground-why-lilly-amazon-and-mastercard-headline-our-new-most-innovative-companies-list/
Cholesterol drug setback casts doubt over multibillion-dollar race : Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) ...
cnbc.com/2026/09/08/novartis-cholesterol-setback-drug-race-eli-lilly-amgen.html
Novo Nordisk vs. Eli Lilly: Who Will Win in the Diet Pill Market?: The pharmaceutical companies Novo Nordisk and Eli Lilly are battling it out for weight-loss ...
wiwo.de/unternehmen/industrie/wegovy-tablette-deutschland-novo-nordisk-eli-lilly/100249818.html
Eli Lilly $LLY agreed to acquire Merida Biosciences for up to $2.875B in cash to bolster its immunology pipeline!
KEY HIGHLIGHTS:
Adds Phase 1 lead asset ... Show more
Aspen Pharmacare sees weight-loss drugs driving earnings: Aspen sells Mounjaro, the weight-loss drug made by US manufacturer Eli Lilly, in South Africa.
semafor.com/article/09/04/2026/aspen-pharmacare-says-weight-loss-drugs-to-drive-profits
STAT Sep 05
Novartis’ experimental cardiovascular drug fails a pivotal study: Other pharmaceutical companies, including Amgen and Eli Lilly, are also developing therapies to ...
statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/
Paid articlePaywallEli Lilly's diabetes drug wins FDA approval to lower heart attack and stroke risk
qz.com/eli-lilly-mounjaro-fda-approval-cardiovascular-diabetes-082826
By mid-2026, retatrutide is a known entity. Eli Lilly's triple GLP-1/ GIP/glucagon agonist has now completed all four core TRIUMPH phase 3 trials plus a ... Show more
By mid-2026, retatrutide is a known entity. Eli Lilly's triple GLP-1/ GIP/glucagon agonist has now completed all four core TRIUMPH phase 3 trials plus a ... Show more
Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear Winner: Zepbound maker Eli Lilly stock broke out of a flat base and reached a record high ...
investors.com/stock-lists/sector-leaders/zepbound-eli-lilly-stock-lly-mounjaro-foundayo/
A single regulatory decision in Britain just opened a door Eli Lilly has been knocking on for years.
Read more: Eli Lilly's Foundayo pill wins first European approval
Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains: While Eli Lilly stock isn't a perfect technical setup, it's still a fundamental powerhouse ...
investors.com/stock-lists/ibd-big-cap-20/eli-lilly-stock-buy-point-earnings/
Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast
dlvr.it/TTsjLD
Eli Lilly tries to stop GLP-1 copycats: Eli Lilly said it filed six lawsuits against US companies it accused of selling illicit versions of its experimental ...
semafor.com/article/08/12/2026/eli-lilly-tries-to-stop-glp-1-copycats
Eli Lilly is offering expanded access to retatrutide, its investigational triple hormone receptor agonist that demonstrated substantial weight loss in phase 3 ... Show more
Read Between These Lines As Lilly, Hot IPO And More Face Key Test: Eli Lilly among stocks to watch with earnings due.
investors.com/research/how-to-find-the-best-stocks-to-buy/eli-lilly-twilio-hinge-health-billiontoone-lead-stocks-to-watch-with-earnings-due/
Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop: Eli Lilly stock charged into a buy zone Wednesday helped by "another exceptional ...
investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q2-2026/
STAT Aug 02
Michigan Supreme Court ruling allows probe into Lilly insulin pricing: Lilly was accused of charging “grossly” excessive prices for different insulin products ...
statnews.com/pharmalot/2026/08/02/michigan-supreme-court-ruling-allows-probe-into-lilly-insulin-pricing/
Paid articlePaywall
Novo Nordisk sued rival Eli Lilly in a U.S. federal court on July 21, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines ... Show more
Security Check
Security Check
Eli Lilly retatrutide access: Who qualifies for the new obesity drug: Eli Lilly will give some adults with severe obesity early access to experimental ...
houstonchronicle.com/news/houston-texas/trending/article/eli-lilly-retatrutide-22373187.php
Goldman Sachs sees writing on the wall for Eli Lilly stock
Read more: Goldman Sachs says one number will move Eli Lilly stock
Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover: Eli Lilly tripped into the psychedelics space Thursday with the up-to-$3 ...
investors.com/news/technology/eli-lilly-ataibeckley-acquisition-psychedelic-drugs/
Barron's Jul 31
New GLP-1s Are on the Way. They’ll Treat a Lot More Than Obesity.
barrons.com/articles/glp-1-obesity-drugs-eli-lilly-novo-nordisk-stocks-19200dcc
Paid articlePaywall Richmond ranks as No. 2 city on the rise, and data centers are a reason why: Massive companies have chosen the region for expansion. Lego is building a massive ...
richmond.com/news/local/business/article_8de7b13e-452f-4316-8762-7546b93e2b2a.html
The world is desperate for weight-loss drugs. But Big Pharma can’t advertise them globally
edition.cnn.com/2026/07/21/business/glp1-weight-loss-drug-advertising
What's next for Lilly-Invest in Alzey?: In the dispute over healthcare reform, the company has announced its intention to stick to its cost-cutting plans ...
allgemeine-zeitung.de/lokales/alzey/wie-es-mit-dem-lilly-invest-in-alzey-weitergeht-5873763
Paid articlePaywall Despite legal amendment: Lilly remains firm on investment cuts in Alzey: Following protests from the pharmaceutical industry, the government removed the biggest ...
allgemeine-zeitung.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/trotz-gesetzeskorrektur-lilly-bleibt-bei-alzey-invest-hart-5869341
Paid articlePaywall
Tampa General sues Eli Lilly over 340B discount freeze: Eli Lilly is withholding pharmaceutical discounts under the 340B Drug Pricing Program from hospitals that ...
modernhealthcare.com/providers/mh-tampa-general-hospital-eli-lilly-340b-lawsuit/
Stocks To Watch: 14 Names Test And Tease New Buy Zones: A barrage of stocks to watch like Eli Lilly and Deere show promise, alongside reminders to keep risk ...
investors.com/research/breakout-stocks-technical-analysis/stocks-to-watch-14-names-test-and-tease-new-buy-zones/
Medicare introduced a new program capping senior costs for GLP-1 weight loss drugs at just $50 a month, projecting a $1B + yearly revenue boost for Eli Lilly ... Show more
Warken's Contribution Stabilization Act: Boehringer/Lilly Get What They Want: In the struggle over the health care savings package, the CDU/CSU and SPD have ...
allgemeine-zeitung.de/politik/politik-deutschland/gesundheitsreform-boehringerlilly-bekommen-was-sie-wollen-5851389
Paid articlePaywall
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China - Eli Lilly (NYSE:LLY)
benzinga.com/news/health-care/26/07/60226245/innovent-eli-lilly-partner-to-commercialize-breast-cancer-drug-in-china
Eli Lilly Approved Obesity Drug for Mystery 79-Year-Old Patient: Questions are swirling over Donald Trump’s health after a bombshell report revealed a mystery ...
newrepublic.com/post/212206/eli-lilly-obesity-drug-79-year-old-patient-trump-health
STAT Jun 25
The mysterious case of Eli Lilly's obesity drug: Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? And why are drugmakers spending so ...
statnews.com/2026/06/25/readout-loud-podcast-eli-lilly-fda-obesity-trump-absci-regenxbio/
Key FactsEarly Use of Experimental Obesity Drug Sparks Speculation
Jun 24, 2026 · Reading time: ~45 sec.
Summary created with AI assistance · Source: futurism.com
Summary created with AI assistance · Source: futurism.com
- A 79-year-old individual gained early access to retatrutide, a promising weight loss drug not yet approved by the FDA.
- The drug was provided through the FDA’s compassionate use program, typically reserved for serious medical cases.
- Although the patient’s identity remains unconfirmed, evidence suggests the person is well-connected and possibly famous.
- The White House denied that President Trump received the drug, despite initially ambiguous responses.
this application was not for the President.— Kush Desai, White House spokesperson; refuting the suggestion that the drug was for the President.
President Donald Trump held the stage for more than 80 minutes as production lines were idled at Mack Trucks in Pennsylvania's Lehigh County ... Show more
pennlive.com
pennlive.com
Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)
benzinga.com/news/health-care/26/06/60074425/eli-lilly-abbisko-expand-drug-hunt-with-1-9-billion-research-pact
White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
thehill.com/homenews/administration/5937098-white-house-denies-trump-retatrutide/
STAT Jun 18
What’s next for GLP-1 weight loss drugs?: Pfizer, Amgen look to compete with Novo Nordisk and Eli Lilly for lucrative weight loss drug sales ...
statnews.com/2026/06/18/weight-loss-drug-market-update-status-report-alex-hogan/
STAT Jun 18
Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data
statnews.com/pharmalot/2026/06/18/eli-lilly-340b-hospitals-drug-discount-price-breaks-eliminated/
Paid articlePaywall Barron's Jun 08
Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.
barrons.com/articles/eli-lilly-stock-novo-nordisk-weight-loss-02bcd4bc
Paid articlePaywallChai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC ... Show more
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says: Retatrutide, an experimental injectable drug, targets three hormones related to weight loss.
time.com/article/2026/05/21/eli-lilly-new-weight-loss-drug/
Key FactsEli Lilly Unveils Breakthrough Triple-Hormone Weight Drug
May 21, 2026 · Reading time: ~45 sec.
Summary created with AI assistance · Source: time.com
Summary created with AI assistance · Source: time.com
- Retatrutide targets three hormones simultaneously, making it more effective than existing GLP-1-based treatments.
- Clinical trials demonstrated weight loss comparable to bariatric surgery, with participants shedding up to 28% of body mass in 1.5 years.
- About 11% discontinued the drug due to side effects, a rate similar to other drugs in the same category.
- Ongoing studies aim to explore further health benefits and compare retatrutide directly with tirzepatide by late 2026.
Right now, it seems both medicines are future mainstays in the treatment of obesity.— Kenneth Custer, executive vice president at Lilly and president of cardiometabolic health, commenting on the potential role of obesity drugs after the retatrutide study results.
Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know: The drugmaker announced it will buy three privately held vaccine makers in deals ...
cnbc.com/2026/05/27/eli-lilly-makes-a-new-push-into-vaccines-heres-what-to-know.html
Lilly und Boehringer: Pharmakonzerne streichen Pläne in Deutschland zusammen: Der US-Pharmakonzern Lilly halbiert seine geplante Investition in Alzey ...
swr.de/swraktuell/rheinland-pfalz/boehringer-ingelheim-el-lilly-alzey-stoppen-investitionen-100.html
Key FactsBoehringer Halts €900M Investments in Germany
Jun 4, 2026 · Reading time: ~45 sec.
Summary created with AI assistance · Source: t-online.de
Summary created with AI assistance · Source: t-online.de
- Boehringer Ingelheim cancels planned investments totaling €900 million at German sites scheduled between 2027 and 2030.
- The company attributes this move to geopolitical shifts and Germany’s upcoming health sector austerity measures involving increased mandatory rebates.
- Markets like the USA and China are becoming more attractive due to focused industrial policies, while Germany’s environment for pharma firms is deteriorating.
- This development reflects intensifying global competition and represents a setback for Chancellor Friedrich Merz’s economic growth agenda.
The next innovation, given the circumstances, is currently not heading to Germany— Médard Schoenmaeckers, Boehringer Ingelheim Germany CEO, according to Handelsblatt
President Donald Trump, earlier this year, bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity drugs ... Show more
Trump bought Lilly stock as his admin boosted its obesity drugs
Trump bought Lilly stock as his admin boosted its obesity drugs
STAT Jun 01
A turning point for pancreatic cancer patients: Today's biotech news features Eli Lilly's two China deals, Akeso's lung cancer bispecific payoff ...
statnews.com/2026/06/01/biotech-news-turning-point-for-pancreatic-cancer-revmed/
Paid articlePaywall
CVS to cover Eli Lilly’s anti-obesity pill, reinstate Zepbound later this year: CVS will cover Eli Lilly’s anti-obesity pill next month, reinstate Zepbound later ...
newschannel5.com/health/medicine/cvs-to-cover-eli-lillys-anti-obesity-pill-reinstate-zepbound-later-this-year
STAT Jun 03
Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
statnews.com/pharmalot/2026/06/03/weight-loss-drugs-knee-replacements-fda-cell-gene-therapy/
Paid articlePaywallTrump Said 'Micron's Great'—And Now Micron's Worth More Than Walmart, Eli Lilly, Berkshire Hathaway - Mic
benzinga.com/markets/prediction-markets/26/06/52923857/trump-said-microns-great-and-now-microns-worth-more-than-walmart-eli-lilly-berkshire-hathaway
Eli Lilly sends strong message on vaccine strategy | LLY: Eli Lilly just dropped nearly $4B on 3 vaccine companies.
thestreet.com/investing/stocks/eli-lilly-lly-stock-sends-strong-message-on-vaccine-strategy
STAT May 25
Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study: Lilly acquired VERV-102 in $1 billion deal with Verve Therapeutics ...
statnews.com/2026/05/25/eli-lilly-verv-102-gene-editing-cholesterol-phase-1-trial-data/
Paid articlePaywall STAT May 26
Five biotech news updates to stay on top of today: Today's biotech news covers Eli Lilly spending more of its GLP-1 cash, Humira's masterclass in ...
statnews.com/2026/05/26/biotech-news-eli-lilly-spends-more-of-its-glp-1-cash/
Paid articlePaywall
Guy ODs on Experimental Weight Loss Drug, Then His Bowels Declare War: Unfortunately for one man who overdosed on an experimental weight loss drug ...
vice.com/en/article/guy-ods-on-experimental-weight-loss-drug-then-his-bowels-declare-war/
Trump Bought Stock in Drugmaker Whom It Then Boosted Through Policy: The president made trades in Eli Lilly early this year while making decisions benefiting the ...
kffhealthnews.org/health-industry/trump-stock-trades-eli-lilly-glp-1-weight-loss-drugs-invest-ethics-disclosures/
Trump invests in Eli Lilly – Suspicions of insider trading: Whether it's Eli Lilly, Apple, or Nvidia: Trump's company buys shares in companies shortly ...
n-tv.de/wirtschaft/Trump-investiert-in-Eli-Lilly-Verdacht-auf-Insiderhandel-id30842013.html
Barron's May 04
FDA Reports Liver Failure in Patient Taking Eli Lilly’s Foundayo: The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli ...
barrons.com/articles/lilly-foundayo-liver-failure-fda-e1ac5d1c
Paid articlePaywall Lilly's Next Obesity Drug Is So Powerful It's Already Getting Copied: Eli Lilly's next obesity drug, retatrutide, is so popular it's already getting copied ...
investors.com/news/technology/eli-lilly-weight-loss-drug-retatrutide-black-market/
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence - Eli Lilly (NYSE:L
benzinga.com/news/health-care/26/05/52288104/eli-lilly-advances-as-inflammatory-bowel-disease-drug-reinforces-long-term-confidence
Eli Lilly Q1 2026 earnings: Mounjaro, Zepbound drive strong results: U.S. sales of Zepbound, Lilly's obesity drug, hit $4.16 billion, an 80% year-over-year gain ...
qz.com/eli-lilly-q1-2026-earnings-mounjaro-zepbound-revenue-guidance-043026
Eli Lilly saw first-quarter profits double as sales of its GLP-1 drug soared.
Barron's Apr 27
As Investors Focus on Lilly’s Foundayo, They May Be Overlooking Another Key Catalyst
barrons.com/articles/eli-lilly-stock-foundayo-eloralintide-obesity-drug-catalyst-cf5310ba
Paid articlePaywall Challenges of Placebo Arms in Weight-Loss Drug Trials: Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing ...
medscape.com/viewarticle/challenges-placebo-arms-weight-loss-drug-trials-2026a1000cy7
STAT Apr 24
A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B: Kelonia came within a week of running out of cash three times. Now it's being ...
statnews.com/2026/04/24/eli-lilly-kelonia-therapeutics-interview/
Paid articlePaywallEli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
cnbc.com/2026/04/20/eli-lilly-to-acquire-cancer-drug-maker-kelonia.html
Eli Lilly and Indiana are partnering to explore and deploy nuclear energy options to Indiana's grid. See link below ⬇️
📸 Michelle ... Show more
Braun, Eli Lilly enter agreement to add nuclear energy to IN grid
Braun, Eli Lilly enter agreement to add nuclear energy to IN grid
Eli Lilly’s CEO is ‘disappointed’ that only 1 in 10 Americans are on GLP-1s: “We look at that as disappointing on the one hand because our job is to get ...
semafor.com/article/04/17/2026/eli-lilly-ceo-david-ricks-wants-more-americans-on-glp-1-drugs
Barron's Apr 22
Eli Lilly Is More Than GLP-1 Drugs. The Stock Looks Attractive.: The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly’s expansion into ...
barrons.com/articles/eli-lilly-more-than-glp-1-drugs-buy-stock-looks-attractive-26cc6a2d
Paid articlePaywall How CVS And Amazon Chipped Away At Eli Lilly, Novo Nordisk Stocks: Eli Lilly and Novo Nordisk stocks took a header Tuesday on reports CVS Health opted out of ...
investors.com/news/technology/eli-lilly-novo-nordisk-viking-therapeutics-amazon-weight-loss-drugs/
